Erwin Woff

Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel

P. Flamen, T. Gil, T. Roumeguère, 2023, Clinical nuclear medicine.

Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer

P. Flamen, M. Paesmans, L. Ameye, 2019, The Journal of Nuclear Medicine.

Metabolic Active Tumor Volume and Total Lesion Glycolysis by 18 F-FDG PET/CT Validated as Prognostic Imaging Biomarkers in Chemorefractory Metastatic Colorectal Cancer

P. Flamen, M. Paesmans, L. Ameye, 2018 .

Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial

P. Flamen, F. Rothé, E. Trevisi, 2020, Cancers.

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

S. Rorive, B. Neyns, V. del Marmol, 2015, Melanoma research.